Eli Lilly’s late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.

Obesity therapeutics now represent ~$98B and 4.6% share, climbing to the fourth-largest category, with ~190 pipeline assets ...

New protocol generated glucose-responsive SC-islets from eight hPSC lines tested, demonstrating potential for autologous ...

Researchers at Karolinska Institutet and KTH Royal Institute of Technology in Sweden have developed an improved method for ...

Learn why GLP-1 use isn’t included in how experts define type 2 diabetes remission despite the drugs’ ability to help manage blood sugar and reduce a person’s A1C.

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...

A recent study revealed that nearly one in 10 people may show minimised response to GLP-1 receptor agonists, commonly used ...

Johns Hopkins engineers are developing treatments for Type 1 diabetes that don't rely on daily insulin injections or wearing an insulin pump to manage blood sugar levels. Instead, their new cell-based ...

Patients with T2D who have a history of depression, especially a recent episode, are more likely to undergo earlier treatment ...

Chronic diseases such as diabetes shouldn’t be taken lightly. While lifestyle changes help manage the problem, they are not a ...